VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma

Ann Oncol. 2010 Feb;21(2):431-432. doi: 10.1093/annonc/mdp548. Epub 2009 Nov 26.

Authors

A Ravaud¹, L Digue², N Trufflandier³, D Smith²

Affiliations

¹ Department of Medical Oncology, Hôpital Saint André, Bordeaux University Hospital, CHU Bordeaux; Bordeaux University Hospital, Victor Segalen; Clinical Investigational Center, INSERM 005, Bordeaux, France. Electronic address: [email protected].
² Department of Medical Oncology, Hôpital Saint André, Bordeaux University Hospital, CHU Bordeaux; Clinical Investigational Center, INSERM 005, Bordeaux, France.
³ Department of Medical Oncology, Hôpital Saint André, Bordeaux University Hospital, CHU Bordeaux.

PMID: 19945958
DOI: 10.1093/annonc/mdp548

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / therapeutic use
Benzenesulfonates / administration & dosage
Benzenesulfonates / adverse effects
Carcinoma, Renal Cell / drug therapy*
Carcinoma, Renal Cell / pathology
Drug Administration Schedule
Drug Resistance, Neoplasm / physiology*
Humans
Indoles / administration & dosage
Kidney Neoplasms / drug therapy*
Kidney Neoplasms / pathology
Male
Middle Aged
Neoplasm Metastasis
Niacinamide / analogs & derivatives
Phenylurea Compounds
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / therapeutic use*
Pyridines / administration & dosage
Pyridines / adverse effects
Pyrroles / administration & dosage
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors*
Sorafenib
Sunitinib
Time Factors

Substances

Antineoplastic Agents
Benzenesulfonates
Indoles
Phenylurea Compounds
Protein Kinase Inhibitors
Pyridines
Pyrroles
Niacinamide
Sorafenib
Receptors, Vascular Endothelial Growth Factor
Sunitinib